PACIRA BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
PACIRA BIOSCIENCES, INC. (PCRX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $1.35 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-01.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2013-03-07
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2012-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2010 was $1.69M, a 215.08% increase from fiscal 2009.
- PACIRA BIOSCIENCES, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2009 was $537.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $1.35M 10-Q · filed 2012-11-01 | ||
| 2012-06-30 | $1.35M 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | $1.69M 10-K · filed 2013-03-07 | |||
| 2009-12-31 | $537.00K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |